Delpharm, a CDMO, has expanded its pharmaceutical network with the acquisition of Astellas’ Meppel pharmaceutical manufacturing facility in the Netherlands.   The fully equipped facility with state-of-the-art technologies is 31,600 square meters and employs 410 qualified personnel who contribute to the production of solid dosage forms, such as tablets, capsules and pellets. The site produces more than 40 million finished products packaged annually.   Meppel site holds quality authorizations ...